NO20054321L - UV-stabilt transdermalt terapeutisk plaster - Google Patents

UV-stabilt transdermalt terapeutisk plaster

Info

Publication number
NO20054321L
NO20054321L NO20054321A NO20054321A NO20054321L NO 20054321 L NO20054321 L NO 20054321L NO 20054321 A NO20054321 A NO 20054321A NO 20054321 A NO20054321 A NO 20054321A NO 20054321 L NO20054321 L NO 20054321L
Authority
NO
Norway
Prior art keywords
transdermal therapeutic
active substance
radiation absorbent
matrix containing
stable transdermal
Prior art date
Application number
NO20054321A
Other languages
English (en)
Other versions
NO336108B1 (no
Inventor
Jan-Peter Ingwersen
Jochen Schumacher
Manfred Suesse
Michael Dittgen
Stephan Mletzko
Thomas Langguth
Dirk Schenk
Hubert Kaffl
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NO20054321L publication Critical patent/NO20054321L/no
Publication of NO336108B1 publication Critical patent/NO336108B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen vedrører et UV-stabilt, transdermalt terapeutisk system (TTS) bestående av et baksidelag, minst én matriks som inneholder et aktivt stoff, og eventuelt en fjernbar film og et UV-strålingsabsorpsjonsmiddel. Et klebelag inneholdende UV-strålingsabsorpsjonsmidlet er innordnet mellom baksidelaget og matriksen som inneholder et aktivt stoff, som er lengst mulig borte fra en overflate, et skillelag er innordnet mellom klebelaget som inneholder UV-strålingsabsorpsjonsmidlet, og matriksen som inneholder et aktivt stoff, som er så fjernt som mulig fra overflaten som er ugjennomtrengelig for det aktive stoff og UV-strålingsabsorpsjonsmidlet. Det oppfinneriske transdermale terapeutisk system oppviser en høy stabilitet og er fri for ulemper ved eksisterende TTS som inneholder et lysfølsomt stoff.
NO20054321A 2003-02-21 2005-09-20 Transdermalt terapeutisk system (TTS) bestående av et baksidelag, av minst én aktiv bestanddel-inneholdende matriks og eventuelt av et avtakbart ark, og som omfatter et UV-absorpsjonsmiddel. NO336108B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster
PCT/EP2004/001052 WO2004073696A1 (de) 2003-02-21 2004-02-04 Uv-stabiles transdermales pflaster

Publications (2)

Publication Number Publication Date
NO20054321L true NO20054321L (no) 2005-09-20
NO336108B1 NO336108B1 (no) 2015-05-18

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054321A NO336108B1 (no) 2003-02-21 2005-09-20 Transdermalt terapeutisk system (TTS) bestående av et baksidelag, av minst én aktiv bestanddel-inneholdende matriks og eventuelt av et avtakbart ark, og som omfatter et UV-absorpsjonsmiddel.

Country Status (31)

Country Link
US (3) US8486443B2 (no)
EP (1) EP1594483B1 (no)
JP (1) JP4528296B2 (no)
KR (1) KR100704825B1 (no)
AR (1) AR043248A1 (no)
AT (1) ATE333271T1 (no)
AU (1) AU2004212675B2 (no)
BR (1) BRPI0407615B8 (no)
CA (1) CA2515918C (no)
CR (1) CR7952A (no)
CY (1) CY1105716T1 (no)
DE (1) DE502004000988D1 (no)
DK (1) DK1594483T3 (no)
EA (1) EA008098B1 (no)
EC (1) ECSP056030A (no)
ES (1) ES2270345T3 (no)
HK (1) HK1085394A1 (no)
HR (1) HRP20050828B1 (no)
IL (1) IL170295A (no)
IS (1) IS2541B (no)
ME (2) ME00147B (no)
MX (1) MXPA05008778A (no)
NO (1) NO336108B1 (no)
NZ (1) NZ541807A (no)
PE (1) PE20041028A1 (no)
PL (1) PL219030B1 (no)
PT (1) PT1594483E (no)
RS (1) RS50428B (no)
SI (1) SI1594483T1 (no)
UY (1) UY28189A1 (no)
WO (1) WO2004073696A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594483B1 (de) 2003-02-21 2006-07-19 Schering AG Uv-stabiles transdermales pflaster
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
CN101005833A (zh) * 2004-08-20 2007-07-25 3M创新有限公司 具有半透明保护膜的透皮药物递送装置
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20100008966A1 (en) * 2008-07-14 2010-01-14 Surmodics, Inc. Medical Devices and Methods for Delivery of Nucleic Acids
CN103189064B (zh) 2010-09-06 2015-08-12 拜耳知识产权有限责任公司 具有高药物释放的低剂量透皮贴剂
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2737464C2 (ru) 2015-12-30 2020-11-30 Кориум Интернэшнл, Инк. Системы и способы длительного трансдермального введения
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (no) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
WO1990004397A1 (de) 1988-10-27 1990-05-03 Schering Aktiengesellschaft Berlin Und Bergkamen Mittel zur transdermalen applikation enthaltend gestoden
EP0453396B1 (de) 1990-03-30 1995-12-13 Ciba SC Holding AG Lackzusammensetzungen
AU633733B2 (en) 1990-05-17 1993-02-04 Hisamitsu Pharmaceutical Co., Inc. Percutaneous preparation containing estradiol
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
PT99338A (pt) 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) * 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
EP0787488A4 (en) 1994-11-18 1998-06-03 Hisamitsu Pharmaceutical Co TRANSDERMAL ABSORBABLE PLASTER
JP3908795B2 (ja) 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) * 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
ID23512A (id) 1997-04-16 2000-04-27 Hisamitsu Pharmaceutical Co Komposisi dasar untuk penyerapan melalui kulit dan sediaan yang dapat diserap melalui kulit yang mengandung komposisi dasar
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
AU3478200A (en) 1999-02-02 2000-08-25 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
EP1197212A4 (en) 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
PT1242012E (pt) 1999-11-24 2010-03-31 Agile Therapeutics Inc Sistema e processo melhorado de libertação transdérmica de contraceptivo
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CN1245961C (zh) 2000-03-17 2006-03-22 久光制药株式会社 紫外遮蔽性贴剂
AU6425601A (en) * 2000-06-13 2001-12-24 Hisamitsu Pharmaceutical Co Plaster
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
AU2002235155A1 (en) 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
EP1485103A1 (en) 2002-03-11 2004-12-15 Janssen Pharmaceutica N.V. Sulfatase inhibiting continuous progestogen contraceptive regimens
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP1594483B1 (de) 2003-02-21 2006-07-19 Schering AG Uv-stabiles transdermales pflaster
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
DE602004018156D1 (de) 2003-08-25 2009-01-15 Bfs Diversified Products Llc Verfahren und vorrichtung zur überwachung der druckfestigkeit von isolierplatten
CN100415777C (zh) 2003-09-11 2008-09-03 西巴特殊化学品控股有限公司 通过多相聚合技术制备的光稳定剂水基浓缩产品形式
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
EA011160B1 (ru) 2003-12-12 2009-02-27 Шеринг Акциенгезельшафт Композиция для трансдермальной доставки гормонов без необходимости использования агентов, усиливающих проникновение, и ее применения
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
JP2012504609A (ja) 2008-10-06 2012-02-23 マイラン・テクノロジーズ，インコーポレイテッド アモルファスロチゴチン経皮システム

Also Published As

Publication number Publication date
AU2004212675B2 (en) 2006-06-01
PT1594483E (pt) 2006-12-29
IS8031A (is) 2005-09-15
KR20050103499A (ko) 2005-10-31
CA2515918C (en) 2010-11-16
US9095691B2 (en) 2015-08-04
ME00147B (me) 2010-10-10
US8486443B2 (en) 2013-07-16
MXPA05008778A (es) 2006-05-25
DE502004000988D1 (de) 2006-08-31
EA200501224A1 (ru) 2006-04-28
PL219030B1 (pl) 2015-03-31
MEP14008A (en) 2010-06-10
JP2006518348A (ja) 2006-08-10
HRP20050828B1 (hr) 2013-10-25
JP4528296B2 (ja) 2010-08-18
NZ541807A (en) 2009-07-31
RS50428B (sr) 2009-12-31
US20150335658A1 (en) 2015-11-26
BRPI0407615A (pt) 2006-02-14
CA2515918A1 (en) 2004-09-02
SI1594483T1 (sl) 2006-12-31
US20130226113A1 (en) 2013-08-29
WO2004073696A1 (de) 2004-09-02
ES2270345T3 (es) 2007-04-01
RS20050639A (en) 2007-09-21
NO336108B1 (no) 2015-05-18
UY28189A1 (es) 2004-04-30
BRPI0407615B8 (pt) 2021-05-25
ECSP056030A (es) 2006-01-27
ATE333271T1 (de) 2006-08-15
BRPI0407615B1 (pt) 2018-02-14
PE20041028A1 (es) 2005-02-18
IL170295A (en) 2010-05-31
EP1594483A1 (de) 2005-11-16
IS2541B (is) 2009-09-15
EA008098B1 (ru) 2007-02-27
EP1594483B1 (de) 2006-07-19
KR100704825B1 (ko) 2007-04-09
CY1105716T1 (el) 2010-12-22
US20060251707A1 (en) 2006-11-09
CR7952A (es) 2006-02-06
HK1085394A1 (en) 2006-08-25
HRP20050828A2 (en) 2006-03-31
PL378035A1 (pl) 2006-02-20
AR043248A1 (es) 2005-07-20
AU2004212675A1 (en) 2004-09-02
DK1594483T3 (da) 2006-11-20

Similar Documents

Publication Publication Date Title
NO20054321L (no) UV-stabilt transdermalt terapeutisk plaster
ES2581985T3 (es) Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal
NO20053663L (no) Transdermal granistetron
AR097045A2 (es) Sistema terapéutico transdérmico
DK1339397T3 (da) Absorptionsmidler og dæklag som er impermeable for aktive stoffer og som indeholder kanaldannere eller aftageligt beskyttelseslag for et transdermalt terapeutisk system
UY29875A1 (es) Compuestos quimicos
DOP2006000168A (es) Dispositivos transdérmicos de liberación de fármaco que contienen drospirenona y métodos de liberación de los mismos
UY30736A1 (es) Compuestos quimicos 537
AR058843A1 (es) Panel de barrera
FI954497A0 (fi) Aktiivista ainetta sisältävä laastari estradiolin vapauttamiseksi ihoon
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
HUP0204448A2 (en) Trnasdermal therapeutic system for the delivery of lerisetron
ZA200509384B (en) Method and device for improving the permeability of the human skin
CY1115757T1 (el) Στερεο διαδερμικο θεραπευτικο συστημα που περιλαμβανει uv-απορροφητη
DK1587500T3 (da) Forbindelser til oral dosering af et aktivt stof, der kræver smagsmaskering
TR200301614A2 (tr) Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas
ATE291902T1 (de) Pharmazeutische zusammensetzung zur verabreichung von beflotaxone
AR022956A1 (es) Sistema transdermal terapeutico y procedimiento para su fabricacion
BRMU8400229U (pt) Bandagem absorvente adesiva hipoalérgica
RU2001101443A (ru) Чрескожная терапевтическая система, содержащая гормоны и ингибиторы кристаллизации

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MM1K Lapsed by not paying the annual fees